HCW Biologics Statistics
Share Statistics
HCW Biologics has 37.82M shares outstanding. The number of shares has increased by 5.14% in one year.
| Shares Outstanding | 37.82M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 19.75M |
| Failed to Deliver (FTD) Shares | 24.81K |
| FTD / Avg. Volume | 0.27% |
Short Selling Information
The latest short interest is 8.09K, so 0.02% of the outstanding shares have been sold short.
| Short Interest | 8.09K |
| Short % of Shares Out | 0.02% |
| Short % of Float | 0.04% |
| Short Ratio (days to cover) | 0.28 |
Valuation Ratios
The PE ratio is -1.77 and the forward PE ratio is -0.57.
| PE Ratio | -1.77 |
| Forward PE | -0.57 |
| PS Ratio | 15.55 |
| Forward PS | 8.7 |
| PB Ratio | 3.28 |
| P/FCF Ratio | -1.54 |
| PEG Ratio | n/a |
Enterprise Valuation
HCW Biologics Inc. has an Enterprise Value (EV) of 47.05M.
| EV / Earnings | -1.88 |
| EV / Sales | 16.56 |
| EV / EBITDA | -2 |
| EV / EBIT | -1.83 |
| EV / FCF | -1.64 |
Financial Position
The company has a current ratio of 0.73, with a Debt / Equity ratio of 0.47.
| Current Ratio | 0.73 |
| Quick Ratio | 0.73 |
| Debt / Equity | 0.47 |
| Total Debt / Capitalization | 31.89 |
| Cash Flow / Debt | -3.57 |
| Interest Coverage | -90.86 |
Financial Efficiency
Return on equity (ROE) is -1.86% and return on capital (ROIC) is -130.11%.
| Return on Equity (ROE) | -1.86% |
| Return on Assets (ROA) | -0.88% |
| Return on Capital (ROIC) | -130.11% |
| Revenue Per Employee | 63.15K |
| Profits Per Employee | -555.43K |
| Employee Count | 45 |
| Asset Turnover | 0.1 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -66.67% in the last 52 weeks. The beta is 0.84, so HCW Biologics 's price volatility has been higher than the market average.
| Beta | 0.84 |
| 52-Week Price Change | -66.67% |
| 50-Day Moving Average | 0.51 |
| 200-Day Moving Average | 0.87 |
| Relative Strength Index (RSI) | 42.67 |
| Average Volume (20 Days) | 9.32M |
Income Statement
In the last 12 months, HCW Biologics had revenue of $2.84M and earned -$24.99M in profits. Earnings per share was $-0.7.
| Revenue | 2.84M |
| Gross Profit | 560.36K |
| Operating Income | -25.72M |
| Net Income | -24.99M |
| EBITDA | -23.58M |
| EBIT | -25.72M |
| Earnings Per Share (EPS) | -0.7 |
Balance Sheet
The company has $3.60M in cash and $6.30M in debt, giving a net cash position of -$2.71M.
| Cash & Cash Equivalents | 3.60M |
| Total Debt | 6.30M |
| Net Cash | -2.71M |
| Retained Earnings | -70.53M |
| Total Assets | 26.56M |
| Working Capital | -27.97M |
Cash Flow
In the last 12 months, operating cash flow was -$22.51M and capital expenditures -$6.20M, giving a free cash flow of -$28.72M.
| Operating Cash Flow | -22.51M |
| Capital Expenditures | -6.20M |
| Free Cash Flow | -28.72M |
| FCF Per Share | -0.8 |
Margins
Gross margin is 19.72%, with operating and profit margins of -904.96% and -879.52%.
| Gross Margin | 19.72% |
| Operating Margin | -904.96% |
| Pretax Margin | -879.52% |
| Profit Margin | -879.52% |
| EBITDA Margin | -829.62% |
| EBIT Margin | -904.96% |
| FCF Margin | -1.01K% |
Dividends & Yields
HCWB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -189.19% |
| FCF Yield | -205.98% |
Analyst Forecast
Currently there are no analyst rating for HCWB.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | -10.6 |
| Piotroski F-Score | 2 |